Morgan Stanley
JUNS

Morgan Stanley’s Jupiter Neurosciences JUNS Stock Holding History

Morgan Stanley’s Portfolio JUNS Stock Details JUNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-7
Closed -$6K – 8262
2024
Q4 		$6K Buy
+7
New +$5.28K ﹤0.01% 6959

Other funds holding JUNS

UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
TSS
Two Sigma Securities New York $1.16B AUM 36.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Morgan Stanley's JUNS Position: Q1 2025 in Review

Morgan Stanley sold out of Jupiter Neurosciences (JUNS) in Q1 2025, closing a stake of 7 shares — an estimated $6K sold.

Morgan Stanley first reported a position in JUNS in Q4 2024 and held it in 1 quarter. The position peaked at $6K in Q4 2024. 7 funds tracked by Wall St. Rank hold JUNS as of Q1 2025.

  • Morgan Stanley reported no remaining Jupiter Neurosciences position as of Q1 2025 after selling out during the quarter.
  • Morgan Stanley sold 7 Jupiter Neurosciences shares in Q1 2025, an estimated $6K.
  • Morgan Stanley first reported a position in Jupiter Neurosciences in Q4 2024 and held it in 1 quarter.
  • Morgan Stanley's Jupiter Neurosciences position peaked at $6K in Q4 2024.
  • 7 funds tracked by Wall St. Rank held Jupiter Neurosciences as of Q1 2025.

Based on Morgan Stanley's 13F filing for Q1 2025, filed 15 May 2025.